OKYO Pharma to Present at the Bio International ConventionLONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company ...

Urcosimod is a lipid conjugated ChemR23 chemerin peptide agonist designed to reduce inflammation and pain in the eye. Urcosimod ophthalmic solution (0.05% and 0.1%) is currently being evaluated in ...

What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...

The present disclosure that lists Raj Patil, Chief Scientific Officer of OKYO Pharma as a joint Inventor, relates to novel OK-101 chemerin analogs for use in treating various diseases and ...

Chemerin is an adipokine involved in inflammation, adipogenesis, angiogenesis and energy metabolism, and has been hypothesized as a link between obesity and type II diabetes. In humans affected by ...

Dr. Marc Parmentier from The Université Libre de Bruxelles said, "Chemerin is a multifunctional protein of 16 kDa, secreted as an inactive precursor by many cell types, including fibroblasts, myocytes ...

Background: While chemerin has been shown to increase proliferation and migration of systemic vascular smooth muscle cells (SMCs) contributing therefore to the development of hypertension, this ...

Thus, dry eye disease is seen as a major economic burden in public healthcare. OK-113 is an agonist of Chemerin, which belongs to GPCR family of receptors, that inhibits underlying inflammation ...

Chemerin is a chemoattractant that promotes chemotaxis in leukocyte populations that express ChemR23. Human and mouse immature mDCs and pDCs, macrophages, and NK cells respond to chemerin in ex ...